Tag: Treatment
Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD

Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD

Market Development Veteran Lisa Rogan Joins Nuvaira's Executive Team MINNEAPOLIS, Feb 11, 2019 /PRNewswire/ -- Nuvaira , a developer of novel therapeutic medical devices to ...

Lees verder
Kyowa Kirin Announces Mogamulizumab Received Positive CHMP Opinion for the Treatment of Mycosis Fungoides and Sézary Syndrome

Kyowa Kirin Announces Mogamulizumab Received Positive CHMP Opinion for the Treatment of Mycosis Fungoides and Sézary Syndrome

TOKYO, September 21, 2018 /PRNewswire/ -- If approved, mogamulizumab would be the first biologic agent targeting CCR4 to be available for patients in Europe.   Kyowa Hakko ...

Lees verder
Endotronix Raises $45 Million in Series D Financing for the Treatment of Heart Failure

Endotronix Raises $45 Million in Series D Financing for the Treatment of Heart Failure

LISLE, Illinois, Sept. 14, 2018 /PRNewswire/ -- Endotronix, Inc. , a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced the ...

Lees verder
Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc) for the Treatment of Mycosis Fungoides and Sézary Syndrome

TOKYO, August 8, 2018 /PRNewswire/ -- - Poteligeo has been approved for the treatment of the two most common types of Cutaneous T-cell lymphoma (CTCL) in ...

Lees verder
AAIC® 2018 Features First Clinical Trial to Show Intensive Blood Pressure Treatment Reduces New Cases of Mild Cognitive Impairment and Dementia (

AAIC® 2018 Features First Clinical Trial to Show Intensive Blood Pressure Treatment Reduces New Cases of Mild Cognitive Impairment and Dementia (

CONFERENCE ALSO RELEASES FIRST-EVER DEMENTIA DATA IN LGB SENIORS, AND WOMEN'S DEMENTIA RISK RELATED TO REPRODUCTIVE HISTORY CHICAGO, July 25, 2018 /PRNewswire/ -- The first ...

Lees verder
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate

Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate

NOVATO, California, TOKYO and LONDON, May 17, 2018 /PRNewswire/ -- Substantial Healing of Rickets Observed in 72% of Patients Treated with Crysvita Compared to 6% of Patients ...

Lees verder
Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboemboli

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboemboli

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension ...

Lees verder
Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hy

Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditional Marketing Authorisation in Europe for the Treatment of X-Linked Hy

TOKYO, LONDON and NOVATO, California, February 23, 2018 /PRNewswire/ -- Crysvita is the First Treatment for XLH that Targets the Underlying Cause of the Disease Crysvita ...

Lees verder
GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

GW Pharmaceuticals Submits Marketing Authorisation Application in Europe for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome

LONDON, December 29, 2017 /PRNewswire/ -- GW Pharmaceuticals plc , a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from ...

Lees verder
Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion for the Treatment of X-Linked Hypophosphatemia in Children

Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion for the Treatment of X-Linked Hypophosphatemia in Children

TOKYO, LONDON, and NOVATO, California, December 15, 2017 /PRNewswire/ -- If approved, burosumab would be the first targeted disease-modifying treatment for XLH   Kyowa Hakko ...

Lees verder
BizPress.nl